Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267376 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MAPTCELA1KDM4ELMNA | |
| SCHEMBL23199034 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL16272963 | 0.75 | ALDH1A1 (0.38) | ALDH1A1MAPTCELA1KDM4ELMNA | |
| SCHEMBL561288 | 0.75 | CYP1A2 (0.40) | ALDH1A1MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL14129723 | 0.71 | ALDH1A1 (0.52) | ALDH1A1MAPTCELA1KDM4ELMNA | |
| SCHEMBL8596046 | 0.70 | ALDH1A1 (0.45) | ALDH1A1MAPTCELA1KDM4ELMNA | |
| SCHEMBL25099 | 0.69 | TDP1 (0.51) | ALDH1A1MAPTLMNAHPGDNPSR1 | |
| SCHEMBL4888381 | 0.69 | NPC1 (0.38) | ALDH1A1MAPTCELA1KDM4ELMNA | |
| SCHEMBL14129737 | 0.68 | ALDH1A1 (0.48) | ALDH1A1MAPTCELA1KDM4ELMNA | |
| SCHEMBL8397225 | 0.67 | ALDH1A1 (0.78) | ALDH1A1MAPTKDM4EHPGDIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | claimed |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-05 | — | — | US | claimed |
| US-7297816-B2 | Sulfonamide compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-20 | — | — | US | claimed |
| EP-1814893-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | claimed |
| US-7199105-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | claimed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | claimed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | claimed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | claimed |
| WO-2023190912-A1 | POLAR-GROUP-CONTAINING OLEFIN COPOLYMER AND METHOD FOR PRODUCING SAME | 日本ポリケム株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| US-10653795-B2 | — | — | 2020-05-19 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| EP-2988783-A1 | HYDROGEL-LINKED PRODRUGS RELEASING MODIFIED DRUGS | Ascendis Pharma A/S (DK) | 2016-03-02 | — | — | EP | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | CCKAR, CCKBR, GRPR | ALDH1A1 1954/4885MAPT 4654/4885CELA1 422/4885 |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | ALDH1A1 2737/4885MAPT 4332/4885CELA1 1870/4885 |
| US-10653795-B2 | — | PTMS, MSN, CD44 | ALDH1A1 219/4885MAPT 2992/4885CELA1 515/4885 |
| US-20100292240-A1 | SULFONAMIDE COMPOUNDS | CCKAR, CCKBR, TAS1R2 | ALDH1A1 2749/4885MAPT 4574/4885CELA1 1027/4885 |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | ALDH1A1 2991/4885MAPT 4461/4885CELA1 1856/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | ALDH1A1 193/4885MAPT 1984/4885CELA1 969/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | ALDH1A1 193/4885MAPT 1984/4885CELA1 969/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | ALDH1A1 2749/4885MAPT 4574/4885CELA1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.